New Options in Constipation Management

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2015 Oct 10

PMID 26449843

Citations 2

Authors

Mellar Davis

Pamela Gamier

Affiliations

Soon will be listed here.

Abstract

Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation.

Citing Articles

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem.

Yoon S, Bruner H Patient Prefer Adherence. 2017; 11:1265-1271.

PMID: 28769555 PMC: 5533475. DOI: 10.2147/PPA.S99412.

Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

McQuade R, Stojanovska V, Abalo R, Bornstein J, Nurgali K Front Pharmacol. 2016; 7:414.

PMID: 27857691 PMC: 5093116. DOI: 10.3389/fphar.2016.00414.

References

Sood R, Ford A . Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Ther Adv Chronic Dis. 2013; 4(6):268-76. PMC: 3807764. DOI: 10.1177/2040622313500110. View

Gaertner J, Siemens W, Camilleri M, Davies A, Drossman D, Webster L . Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2014; 49(1):9-16. DOI: 10.1097/MCG.0000000000000246. View

Lembo A, Camilleri M . Chronic constipation. N Engl J Med. 2003; 349(14):1360-8. DOI: 10.1056/NEJMra020995. View

Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L . Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2006; 13(1):35-7. DOI: 10.1038/nm1521. View

Bruner H, Atayee R, Edmonds K, Buckholz G . Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res. 2015; 8:289-94. PMC: 4472065. DOI: 10.2147/JPR.S61326. View

Drossman D . [Characterization of intestinal function and diagnosis of irritable bowel syndrome by surveys and questionnaires]. Gastroenterol Clin Biol. 1990; 14(5 ( Pt 2)):37C-41C. View

Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P . Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008; 11(3):492-501. DOI: 10.1089/jpm.2007.0200. View

Wong B, Camilleri M . Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opin Pharmacother. 2011; 12(6):983-90. DOI: 10.1517/14656566.2011.566559. View

Lata P, Walbrandt Pigarelli D . Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother. 2002; 37(1):122-6. DOI: 10.1345/aph.1C118. View

10.

Song K . Practical Methods to Assess Chronic Constipation. J Neurogastroenterol Motil. 2015; 21(3):307-8. PMC: 4496910. DOI: 10.5056/jnm15100. View

11.

Paulson D, Kennedy D, Donovick R, Carpenter R, Cherubini M, Techner L . Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial. J Pain. 2005; 6(3):184-92. DOI: 10.1016/j.jpain.2004.12.001. View

12.

Isolauri E, Kalliomaki M, Laitinen K, Salminen S . Modulation of the maturing gut barrier and microbiota: a novel target in allergic disease. Curr Pharm Des. 2008; 14(14):1368-75. DOI: 10.2174/138161208784480207. View

13.

Slatkin N, Lynn R, Su C, Wang W, Israel R . Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011; 42(5):754-60. DOI: 10.1016/j.jpainsymman.2011.02.015. View

14.

Chey W, Camilleri M, Chang L, Rikner L, Graffner H . A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011; 106(10):1803-12. PMC: 3188811. DOI: 10.1038/ajg.2011.162. View

15.

Nullens S, Nelsen T, Camilleri M, Burton D, Eckert D, Iturrino J . Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut. 2011; 61(8):1132-9. PMC: 3813955. DOI: 10.1136/gutjnl-2011-301181. View

16.

Candy B, Jones L, Goodman M, Drake R, Tookman A . Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011; (1):CD003448. DOI: 10.1002/14651858.CD003448.pub3. View

17.

Nagano M, Kuroki S, Mizuta A, Furukawa M, Noshiro M, Chijiiwa K . Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids. 2004; 69(10):701-9. DOI: 10.1016/j.steroids.2004.07.004. View

18.

Simren M, Bajor A, Gillberg P, Rudling M, Abrahamsson H . Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. Aliment Pharmacol Ther. 2011; 34(1):41-50. DOI: 10.1111/j.1365-2036.2011.04675.x. View

19.

Nelson A, Camilleri M . Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015; 8(4):206-20. PMC: 4480571. DOI: 10.1177/1756283X15578608. View

20.

Goldberg M, Li Y, Johanson J, Mangel A, Kitt M, Beattie D . Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010; 32(9):1102-12. DOI: 10.1111/j.1365-2036.2010.04456.x. View